{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:10:37Z","timestamp":1793340637739,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejca.2024.115070","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T17:52:58Z","timestamp":1728669178000},"page":"115070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study"],"prefix":"10.1016","volume":"213","author":[{"given":"Oleksandr","family":"Dudnichenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Penkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"McKean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Mandal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariia","family":"Kukushkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Panella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Cs\u0151szi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gerletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahgull","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Polli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.115070_bib1","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.3361","article-title":"Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas","volume":"47","author":"Krauthammer","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2024.115070_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2024.115070_bib3","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic therapy for melanoma: ASCO guideline update","volume":"41","author":"Seth","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115070_bib4","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.annonc.2020.07.005","article-title":"ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee","volume":"31","author":"Michielin","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.115070_bib5","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.22.02322","article-title":"Contribution of MEK inhibition to BRAF\/MEK inhibitor combination treatment of BRAF-mutant melanoma: part 2 of the randomized, open-label, phase III COLUMBUS Trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115070_bib6","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1200\/JCO.21.02659","article-title":"COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115070_bib7","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.115070_bib8","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.22.01599","article-title":"Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma","volume":"41","author":"Robert","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115070_bib9","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1001\/jamaoncol.2020.4401","article-title":"Rationale for immune checkpoint inhibitors plus targeted therapy in metastatic melanoma: a review","volume":"6","author":"Dummer","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2024.115070_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.smim.2016.01.001","article-title":"Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?","volume":"28","author":"Robert","year":"2016","journal-title":"Semin Immunol"},{"key":"10.1016\/j.ejca.2024.115070_bib11","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejca.2024.115070_bib12","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","article-title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma","volume":"25","author":"Ascierto","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2024.115070_bib13","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.21.01601","article-title":"Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115070_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2024.115070_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.115070_bib16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.115070_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114073","article-title":"COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma","volume":"204","author":"Schadendorf","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924012012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924012012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T08:33:16Z","timestamp":1733992396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924012012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":17,"alternative-id":["S0959804924012012"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115070","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115070"}}